Citadel Advisors LLC grew its position in NanoString Technologies, Inc. (NASDAQ:NSTG) by 54.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,038 shares of the biotechnology company’s stock after buying an additional 27,564 shares during the period. Citadel Advisors LLC owned 0.31% of NanoString Technologies worth $1,261,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Marshall Wace North America L.P. purchased a new stake in shares of NanoString Technologies in the 2nd quarter valued at approximately $4,200,000. Alliancebernstein L.P. purchased a new stake in shares of NanoString Technologies in the 2nd quarter valued at approximately $261,000. Nationwide Fund Advisors grew its stake in shares of NanoString Technologies by 368.4% in the 2nd quarter. Nationwide Fund Advisors now owns 41,098 shares of the biotechnology company’s stock valued at $680,000 after buying an additional 32,323 shares during the period. Candriam Luxembourg S.C.A. grew its stake in shares of NanoString Technologies by 135.6% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 106,000 shares of the biotechnology company’s stock valued at $1,713,000 after buying an additional 61,000 shares during the period. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in shares of NanoString Technologies in the 2nd quarter valued at approximately $485,000. 92.72% of the stock is owned by institutional investors and hedge funds.

NanoString Technologies, Inc. (NSTG) opened at $7.46 on Thursday. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 1.08. NanoString Technologies, Inc. has a 1 year low of $7.20 and a 1 year high of $23.31.

NanoString Technologies (NASDAQ:NSTG) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.11. The firm had revenue of $27.02 million during the quarter, compared to analysts’ expectations of $26.27 million. NanoString Technologies had a negative net margin of 44.24% and a negative return on equity of 174.55%. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.51) EPS. equities analysts expect that NanoString Technologies, Inc. will post -1.77 earnings per share for the current fiscal year.

NSTG has been the subject of several analyst reports. Robert W. Baird dropped their price target on shares of NanoString Technologies from $14.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, November 3rd. Zacks Investment Research raised shares of NanoString Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Cowen reaffirmed a “buy” rating and set a $20.00 price objective on shares of NanoString Technologies in a research report on Thursday, September 28th. Finally, Janney Montgomery Scott cut shares of NanoString Technologies from a “buy” rating to a “neutral” rating in a research report on Thursday, October 12th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. NanoString Technologies has a consensus rating of “Hold” and a consensus target price of $17.25.

COPYRIGHT VIOLATION WARNING: “Citadel Advisors LLC Has $1.26 Million Stake in NanoString Technologies, Inc. (NSTG)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/07/citadel-advisors-llc-has-1-26-million-stake-in-nanostring-technologies-inc-nstg.html.

NanoString Technologies Profile

NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

Institutional Ownership by Quarter for NanoString Technologies (NASDAQ:NSTG)

Receive News & Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.